Zorevunersen in Children and Adolescents with Dravet Syndrome

This study investigates the safety and clinical effects of zorevunersen, an antisense oligonucleotide aimed at up-regulating Na_V1.1 sodium channels, in children and adolescents with Dravet syndrome. The results from phase 1-2a studies indicate that zorevunersen is generally well-tolerated, with some patients experiencing significant reductions in convulsive-seizure frequency and improvements in overall clinical status over 36 months. These findings support the potential of zorevunersen as a disease-modifying treatment for Dravet syndrome.